The cost-effectiveness of screening for anal cancer in men who have sex with men: A systematic review

Sexual Health

Volumn 9, Issue 6, 2012, Pages 610-619

  Howard, Kirsten ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

economics; human papillomavirus; long term health outcomes; modelling.

Indexed keywords

ANUS CANCER; ANUS CARCINOMA; ARTICLE; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MALE HOMOSEXUAL; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ADULT; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CAUSALITY; COMORBIDITY; FEMALE; GREAT BRITAIN; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; MALE; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RISK FACTORS; UNITED STATES; WORLD HEALTH;

EID: 84870452335     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH12017     Document Type: Article

References (48)

1. Spence AR, Franco EL, Ferenczy A. The role of human papillomaviruses in cancer: evidence to date. Am J Cancer 2005; 4(1): 49-64. doi:10.2165/00024669- 200504010-00004
2. Melbye M, Sprogel P. Aetiological parallel between anal cancer and cervical cancer. Lancet 1991; 338(8768): 657-9. doi:10.1016/0140- 6736(91)91233-K
3. Australian Institute of Health and Welfare (AIHW). Cancer incidence to 2008. Canberra: AIHW; 2011. Available from: http://www.aihw.gov.au/cancer-data/ [verified January 2012].
4. Zeller JL, Lynm C, Glass RM. Anal cancer. JAMA 2008; 299(16): 1980. doi:10.1001/jama.299.16.1980
5. D'Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. Journal of Acquired Immune Deficiency Syndromes 2008; 48(4): 491-9. doi:10.1097/QAI.0b013e31817aebfe
6. Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? Journal of Acquired Immune Deficiency Syndromes 2004; 37(5): 1563-5. doi:10.1097/00126334-200412150-00004
7. MR Gold, JE Siegel, LB Russell, MC Weinstein editors. Costeffectiveness in health and medicine. New York: Oxford University Press; 1996.
8. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford, NY: Oxford University Press; 2005.
9. Owens DK. Analytic tools for public health decision making. Medical Decision Making 2002; 22: S3-S10. doi:10.1177/027298902237969
10. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. June 2008. London: NICE; 2008. Available online at: http://www.nice.org.uk/media/b52/a7/taMethodsGuideUpdatedJune2008.pdf [verified January 2012].
11. Department of Health and Ageing (DoHA). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. December 2008. Canberra: DoHA; 2008. Available online at: http://www.health.gov.au/internet/ main/publishing.nsf/content/pbacguidelines-index [verified January 2012].
12. Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G. Costeffectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technology Assessment 2010; 14(53): 1-131.
13. Karnon J, Jones R, Czoski-Murray C, Smith KJ. Cost-utility analysis of screening high-risk groups for anal cancer. J Public Health (Bangkok) 2008; 30(3): 293-304. doi:10.1093/pubmed/fdn045
14. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med 2000; 108(8): 634-41. doi:10.1016/S0002-9343(00)00349-1
15. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999; 281(19): 1822-9. doi:10.1001/jama.281.19.1822
16. Lam JM, Hoch JS, Tinmouth J, Sano M, Raboud J, Salit IE. Cost-effectiveness of screening for anal precancers in HIVpositive men. AIDS 2011; 25(5): 635-42. doi:10.1097/QAD. 0b013e3283434594
17. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12(5): 495-503. doi:10.1097/00002030- 199805000-00011
18. Palefsky JM, Holly EA, Hogeboom CJ, Ralston ML, DaCosta MM, Botts R, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17(4): 314-9. doi:10.1097/ 00042560-199804010-00004
19. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998; 177(2): 361-7. doi:10.1086/ 514194
20. Critchlow CW, Surawicz CM, Holmes KK, Kuypers J, Daling JR, Hawes SE, et al. Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. AIDS 1995; 9(11): 1255-62. doi:10.1097/00002030- 199511000-00007
21. Kiviat NB, Critchlow CW, Holmes KK, Kuypers J, Sayer J, Dunphy C, et al. Association of anal dysplasia and human papillomavirus with immunosuppression and HIV infection among homosexual men. AIDS 1993; 7(1): 43-50. doi:10.1097/ 00002030-199301000-00007
22. Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987; 317(16): 973-7. doi:10.1056/ NEJM198710153171601
23. Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14(5): 415-22. doi:10.1097/00042560- 199704150-00004
24. Peddada AV, Smith DE, Rao AR, Frost DB, Kagan AR. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1997; 37(5): 1101-5. doi:10.1016/S0360- 3016(96)00596-2
25. Bottomley DM, Aqel N, Selvaratnam G, Phillips RH. Epidermoid anal cancer in HIV infected patients. Clin Oncol (R Coll Radiol) 1996; 8(5): 319-22. doi:10.1016/S0936-6555(05)80720-4
26. Mendenhall WM, Sombeck MD, Speer TW, Marsh RD, Carroll RR, Copeland EM. Current management of squamous cell carcinoma of the anal canal. Surg Oncol 1994; 3(3): 135-46. doi:10.1016/0960- 7404(94)90042-6
27. Holland JM, Swift PS. Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. Radiology 1994; 193(1): 251-4.
28. Chadha M, Rosenblatt EA, Malamud S, Pisch J, Berson A. Squamouscell carcinoma of the anus in HIV-positive patients. Dis Colon Rectum 1994; 37(9): 861-5. doi:10.1007/BF02052589
29. Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, et al. The cost-effectiveness of preventing AIDSrelated opportunistic infections. JAMA 1998; 279(2): 130-6. [Erratum appears in JAMA 1999 Jun 2;281(21):1989] doi:10.1001/ jama.279.2.130
30. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13(2): 89-102. doi:10.1177/0272989X9301300202
31. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition specific values. Med Care 1998; 36(6): 778-92. doi:10.1097/ 00005650-199806000-00002
32. Sayers SJ, McMillan A, McGoogan E. Anal cytological abnormalities in HIV-infected homosexual men. Int J STD AIDS 1998; 9(1): 37-40. doi:10.1258/0956462981921017
33. Wong S, Gibbs P, Chao M, Jones I, McLaughlin S, Tjandra J, et al. Carcinoma of the anal canal: a local experience and review of the literature. ANZ J Surg 2004; 74(7): 541-6. doi:10.1111/j.1445- 2197.2004.02943.x
34. Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. Dis Colon Rectum 2002; 45(4): 453-8. doi:10.1007/s10350-004-6219-8
35. Brown SR, Skinner P, Tidy J, Smith JH, Sharp F, Hosie KB. Outcome after surgical resection for high-grade anal intraepithelial neoplasia (Bowen's disease). Br J Surg 1999; 86(8): 1063-6. doi:10.1046/ j.1365-2168.1999.01184.x
36. Marchesa P, Fazio VW, Oliart S, Goldblum JR, Lavery IC. Perianal Bowen's disease: a clinicopathologic study of 47 patients. Dis Colon Rectum 1997; 40(11): 1286-93. doi:10.1007/BF02050810
37. Arnott SJ, Cunningham D, Gallagher J. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Coordinating Committee on Cancer Research. Lancet 1996; 348(9034): 1049-54.
38. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El SH. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 2006; 43(2): 223-33. doi:10.1086/505219
39. Cranston RD, Darragh TM, Holly EA, Jay N, Berry JM, Da CM, et al. Self-collected versus clinician-collected anal cytology specimens to diagnose anal intraepithelial neoplasia in HIV-positive men. Journal of Acquired Immune Deficiency Syndromes 2004; 36(4): 915-20. doi:10.1097/00126334-200408010-00004
40. Arain S, Walts AE, Thomas P, Bose S. The anal Pap smear: cytomorphology of squamous intraepithelial lesions. Cytojournal 2005; 2(1): 4. doi:10.1186/1742-6413-2-4
41. Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med 2001; 111(2): 140-9. doi:10.1016/S0002-9343(01)00780-X
42. Trueman P, Youle M, Sabin CA, Miners AH, Beck EJ. The cost effectiveness of triple nucleoside analogue therapy antiretroviral regimens in the treatment of HIV in the United Kingdom. HIV Clin Trials 2000; 1(1): 27-35. doi:10.1310/P52N-KXJH-1945- UX7X
43. Mauskopf J, Lacey L, Kempel A, Simpson K. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manag Care 1998; 4(7): 1004-12.
44. Palefsky JM, Holly EA, Ralston ML, Arthur SP, Jay N, Berry JM, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17(4): 320-6. doi:10.1097/00042560-199804010-00005
45. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002; 35(9): 1127-34. doi:10.1086/344057
46. Howard K, Salkeld G, Irwig L, Adelstein BA. High participation rates are not necessary for cost-effective colorectal cancer screening. J Med Screen 2005; 12(2): 96-102. doi:10.1258/0969141053908276
47. Salit IE, Lytwyn A, Raboud J, Sano M, Chong S, Diong C, et al. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS 2010; 24(9): 1307-13.
48. Lytwyn A, Salit IE, Raboud J, Chapman W, Darragh T, Winkler B, et al. Interobserver agreement in the interpretation of anal intraepithelial neoplasia. Cancer 2005; 103(7): 1447-56. doi:10.1002/ cncr.20927